We analyzed 113 patients with lymphoma who underwent allogeneic transplantation with reduced-intensity conditioning (allo-RIC) regimens at a single institution, from February 2001 through November 2009, searching for factors predictive of the outcome. At the time of transplantation, 60% of patients were in CR, 29% in PR and 11% had progressive or stable disease. At a median followup of 34 months (confidence interval (CI) 17-45), the 3-year OS and PFS were 59% (CI 48-68%) and 51% (CI 41-61%), respectively. The 100-day and 2-year nonrelapse mortalities (NRM) were 6% and 28% (CI 20-35%), respectively. Grade II-IV acute GVHD (aGVHD) incidence was 38%, and the global incidence of chronic GVHD was 33%. In univariate analysis, OS was influenced by disease status before allo-RIC; aGVHD negatively affected on survival. Similarly, PFS was influenced only by disease status. Histological subtype did not affect OS or PFS. We conclude that disease status at the time of transplantation significantly influences survival in patients receiving allo-RIC for lymphoma, whereas histological subtype does not. This reinforces the need to administer more effective debulking treatments to lymphoma patients, for optimal benefit of allogeneic immune recognition of minimal residual disease, independently from lymphoma histology.
INTRODUCTION
Most patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) are cured with first-line therapy and/or high-dose chemotherapy (HDC) and autologous stem cell support. Patients with relapse after HDC or with disease refractory to several lines of treatment can be rescued with allo-SCT, suggesting the presence of a graft-versus-lymphoma (GVLy) effect. [1] [2] [3] [4] [5] [6] [7] [8] Initially, myeloablative conditioning regimens have been used with a prohibitive nonrelapse-related mortality (NRM) that offset the GVLy effect. 9, 10 Recently, the transplant community has widely adopted the use of reduced-intensity conditioning (allo-RIC) regimen, which resulted in a significant decrease in NRM in patients transplanted for hematological malignancies, even when diagnosed with comorbidities or heavily pretreated and with poor performance status. 11 Several prognostic factors were reported to influence the outcome of patients undergoing allo-SCT for lymphoid malignancies. For HL patients, Robinson et al., 1 on behalf the European Blood and Marrow Transplantation group (EBMT), showed that chemosensitive disease and good performance status were the most important prognostic factors for OS and PFS. Histological subtype is considered an important prognostic factor, suggesting that different sensitivities to the immunological effects of transplantation may exist, depending on the nature of lymphoma cells and the processes underlying transformation. [12] [13] [14] In this retrospective study, we analyzed patients with lymphoma who underwent allo-RIC at a single institution, searching for factors predictive of the outcome.
PATIENTS AND METHODS
From February 2001 to November 2009, 113 lymphoma patients received allo-SCT at Institut Paoli Calmettes. This study was approved by the local institutional review board.
Eligibility criteria
HL patients received allo-RIC in cases of relapse after HDC or refractoriness to salvage chemotherapy in the auto-allo program or when they could not receive HDCT as consolidation therapy because it was impossible to harvest autologous stem cells.
In NHL patients, eligibility criteria were more heterogeneous reflecting the histological characteristics: for T-cell lymphoma, allo-RIC was planned early, after the first-line therapy; for aggressive B-cell lymphoma and mantle cell lymphoma, relapse after HDC was the main indication to allo-RIC, less than PR after second-line salvage therapy, in a tandem auto-allo strategy; for low-grade lymphoma, relapsed after HDC, refractoriness to several line chemotherapies including MoAb. Transformed high-grade NHL patients received allo-RIC when responsive to conventional computed tomography, with or without previous HDC.
Conditioning regimens and GVHD prophylaxis
Patients received a variety of RIC regimens modified over time. RIC regimens consisted of: fludarabine (30 mg/m 2 per day, 5 days), oral or i.v. BU (4 mg/kg or 3.2 mg/kg/day over 2 or 3 days) and thymoglobulin (2.5 mg/kg/day over 1 or 2 days), and GVHD prophylaxis was CYA alone starting from day À 3 at 3 mg/kg/day, and then adjusted on the basis of dose levels; fludarabine (30 mg/m 2 per day for 3 days) and low-dose TBI (2 Gy) with GVHD prophylaxis consisting of CYA and mycophenolate mofetil for 28 or 56 days after transplant depending on donor type (identical sibling vs unrelated donor). These patients were included in a prospective randomized study. 15 Patients receiving cord blood were all conditioned with CY (50 mg/kg, fludarabine (40 mg/m 2 per day, 5 days) and TBI 2 Gy; CYA and mycophenolate mofetil were used for GVHD prophylaxis. Other RIC regimens used are described in Table 1 .
Acute and chronic GVHD (aGVHD and cGVHD) diagnosis, grading and treatment were conducted according to international guidelines, as previously reported. 16 Chimerism analysis was evaluated by PCR amplification of variable number tandem repeat (VNTR) polymorphisms on CD3 þ immuneselected blood lymphocytes sampled at fixed time points, as previously reported. 16 CYA dose management was adjusted on the basis of dose levels (to monitor toxicity), chimerism results and disease status (to modulate engraftment and GVLy effect).
In cases of mixed chimerism (defined as 45% of recipient cells) and for progressing or relapsing patients, whatever chimerism status was found, donor lymphocyte infusions (DLIs) were planned. DLI was also administered in cases of persistent disease. DLI was given in patients out of immunosuppression for at least 1 month, in the absence of clinical signs of GVHD or active infections. In cases with an unrelated donor, 1 Â 10 6 /kg of body weight (BW) of CD3 þ cells were given for the first DLI and 1 Â 10 7 / kg of BW of CD3 þ cells for the second and third DLIs. In cases with matched related donors, dose escalation of CD3 þ cells was: first dose 1 Â 10 7 /kg of recipient BW, and the second and third doses were 1 Â 10 8 / kg of BW. In the absence of GVHD, the time between each DLI was 4-6 weeks.
Donors
Donor mobilization was performed using 5 to 6 days of s.c. G-CSF (10 mg/kg/day; Neupogen, AMGEN, Thousand Oaks, CA, USA). The minimum, optimal and maximal harvested stem cell doses were 2, 4 and 8 Â 10 6 CD34 þ /kg, respectively.
Supportive care
All patients were admitted in single rooms, each equipped with a HEPA filtration system. Antifungal and antibacterial prophylaxis changed during the study period, but all patients received antifungal prophylaxis (either fluconazole, voriconazole or caspofungin), whereas more recently, antibacterial prophylaxis was abandoned. RBC transfusions and single-donor platelet transfusions were administered for Hb level o8 g/L or platelet count o10 Â 10 9 /L, respectively, or whenever indicated by clinical symptoms.
Study definitions and statistical methods
Descriptive analysis of data was performed according to standard methodology. OS was defined as the probability of survival irrespective of disease status at any time point after transplantation. Alive patients were censored at their last follow-up.
PFS was defined as the probability of being alive and free of disease at any time point after transplantation. Thus, death or disease relapse/ progression were treated as events. Patients alive and free of disease were censored at their last follow-up. OS and PFS were estimated by the KaplanMeier method, and compared using log-rank test. Hazard ratios were estimated using a Cox proportional regression model. NRM incidence was defined as the probability of dying from a cause not related to the underlying evolution of malignancies. NRM was estimated by the Prentice method, and compared by the Gray Test. For OS, PFS and NRM end points, a time-dependant Cox model analysis was used to estimate hazard ratios for time-dependant covariables (aGVHD and cGVHD). Data needed for elaborating each of the three scores were collected.
The search for factors potentially influencing NRM and OS was initiated in a univariate analysis.
Statistical analysis was performed using the R.2.11.1 software (R Development Core Team, http://www.R-project.org).
RESULTS
The main patient characteristics are reported in Table 1 . Most patients were diagnosed with NHL (80%), and of these 40% were affected by low-grade NHL. Overall, 72% of patients had previously received HDC that was part of first-line therapy in 28 patients (25%); among those patients, 22 (79%) had relapsed thereafter. Six patients received allo-RIC as part of a planned autoallo program. In all, 53 patients (47%) received HDC in second or subsequent response, and 18 in relapse. At the time of allo-RIC, 89% of patients were considered chemosensitive. The Sorror score was calculated for 106 patients (94%) and equally distributed in the three groups of risk. HLA-identical siblings were the most frequently used stem cell source (86%). A combination of fludarabine, BU/busilvex and antithymocyte globulin was the most frequently used RIC regimen (67%), followed by fludarabine and low-dose TBI (21%). 
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At a median follow-up of 34 months (confidence interval (CI) 17-45), the 3-year OS and PFS were 59% (CI 48-68%) and 51% (CI 41-61%), respectively (Figures 1 and 2 ) for all patients. In all, 25 (22%) patients relapsed or progressed after allo-RIC, and the median time to relapse was 4.4 months (CI 2.6-8.7). Of these patients, 7 (28%) did not receive any therapy because of poor performance status. The first dose of DLI was administered to 16 patients (64%): 12 for relapse or progression, 3 because of persistent lymphoma and 1 for mixed chimerism. A second dose was infused in 7 patients. The median dose of CD3 þ cells was 1 Â 10 7 /kg (range 0.1-1) for the first and 1 Â 10 8 /kg (range 0.6-1.4) for the second dose. Disease response was observed only in two patients treated for persistent disease. No patients with relapse/ progressive disease, at the time of DLI, had clinical response. GVHD with chronic characteristics was observed in 4 patients (25%). Only two progressive patients received CT because of active cGVHD and early extensive disease progression.
At the last follow-up, 66 patients (58%) were alive and 47 patients (42%) had died. The median time to death was 284 days (CI 7-1926) . The 100-day and 2-year NRM were 6% and 28% (CI 20-35%), respectively ( Figure 3 ). The causes of toxic deaths were aGVHD 36% (11/30), cGVHD 23% (7/30), microbiologically not documented pneumonitis 10% (3/30), viral encephalitis 7% (2/30), graft failure 7% (2/30), central nervous system hemorrhage 1, cerebral aspergillosis 1, lung cancer 1 and larynx cancer 1. One patient died of aGVHD after a second allo-RIC for progressive disease. CMV infection was detected in 13 patients (11%) at a median time of 34 days (CI 1-83) after allo-RIC. Only one patient developed documented CMV disease.
The aGVHD incidence was 43%; grade II-IV was 38% (65% grade 2, 18% grade 3 and 17% grade 4); and the median time to diagnosis was 33 days (CI 11-114).
There were 106 evaluable patients for cGVHD; the global incidence was 33% (35/106) and the incidence of extensive forms of cGVHD was 71% (25/35). The median time to cGVHD diagnosis was 152 days (CI 61-599). The NIH (National Institute of Health) scale was used to reclassify cGVHD as follows: mild 31% (11/35), moderate 40% (14/35) and severe 31% (11/35). The mode of apparition of cGVHD was de novo 51% (18/35), quiescent 34% (12/35) and progressive 14% (5/35).
We performed univariate analysis to identify factors influencing the OS and PFS. For OS, the CR status at the time of allo-RIC was significantly associated with outcome (Table 2) . Surprisingly, the histological subtype did not influence the OS, and overall HL and different NHL patient subsets displayed similar OS (Figure 4) . In a time-dependent analysis, the presence of aGVHD was associated with a significantly lower survival (Table 3 ). The multivariate analysis confirms that only disease status at allo-RIC significantly influences the outcome.
Regarding PFS, again disease status at the time of allo-RIC was predictive of outcome. In this analysis, CR and CR plus PR had a significant impact on PFS. As observed for OS, the histological subtypes were not associated with different outcomes (Table 2 and Figure 5 ).
CONCLUSION
Allo-SCT has become a treatment option for patients with advanced or poor prognosis lymphoma, particularly with the greater use of allo-RIC. Several studies have been published showing that a variable proportion of these patients can survive long term, and probably can be considered cured from lymphoma. 7 Robinson et al. 1 showed, in a retrospective study, that better results were observed in low-grade lymphoma, whereas the outcome was poor for mantle cell lymphoma and HL. Similar conclusions, even if with some difference, were reported by Morris et al. 17 for NHL. Corradini et al. 13 analyzed a large cohort of patients, treated with homogenous allo-RIC and HLA-identical sibling donor, and showed that low-grade and aggressive NHL confirmed these data in a cohort of 87 patients receiving allo-RIC with different source of stem cells. In this study, low-grade NHL was the histotype more sensitive to the GVLy effect, which was less evident in mantle cell lymphoma, aggressive lymphoma and HL. Across several studies, disease status before allo-RIC is considered as one of the most important factor to influence the outcome independently from histology. 2, 4, [18] [19] [20] In the present study, we analyzed 113 lymphoma patients receiving allo-RIC at a single institution. Patient characteristics were similar to other studies, with most patients previously treated with HDC, or relapsing after several lines of computed tomography, thus defining a cohort of patients with poor prognosis. However, almost two-thirds of patients were in CR/PR. The 3-year OS and PFS were 58 and 51%, and 3-year TRM was 28%, which are in line with already reported data. In a univariate analysis, the histological subtype did not influence OS or PFS, whereas CR and CR/PR status was significantly associated with the outcome for OS and PFS, respectively. OS was worse in patients with grade II-IV aGVHD, and this was correlated with the impact on NRM, because 33% of deaths were linked to GVHD.
The reasons for this difference from aforementioned studies are not immediate, but the most plausible was the retrospective nature of all these reports that introduced selection bias regarding patient selection, different conditioning regimens, GVHD Disease status in lymphoma patients after RIC regimen and allo-SCT L Castagna et al prophylaxis and different modalities to treat the relapse or progression after transplantation. However, the strength of results obtained in this retrospective study should be read critically. In this optic, a disease risk index recently developed, in which survival after allo-SCT was influenced by a combination of diagnosis and disease status, showed that only indolent lymphomas were considered at low risk whereas all other histologies were at intermediate risk.
